 OUTLINE: This is a multicenter study. Patients receive 17-N-allylamino-17-demethoxygeldanamycin 17-AAG IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response CR receive 2 additional courses of treatment beyond documentation of CR. 